Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University — Biomedical Watch V2

Traitements4programmes

Essais1liés

Publications6liées

SourceDBlocale

Traitements

4

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
BendamustineResearchers are looking for new ways to treat follicular lymphoma (FL). A standard (usual) treatment for FL includes a targeted therapy called rituximab and chemotherapy. In this study, researchers want to learn if giving a study medicine called MK-1045 and rituximab can treat FL. MK-1045 is a type of treatment called immunotherapy. The goals of this study are to learn: * About the safety of MK-1045 and rituximab, and if people tolerate them when given together * If people who receive MK-1045 and rituximab have the cancer go away * If people who receive MK-1045 and rituximab live longer without their cancer getting worse compared to those who receive standard treatment (rituximab and chemotherapy)	Cancer, SEP	Phase 1/2	À vérifier	United States	À vérifier
CT ScanThe Phase I part of the study will apply to identify dose-limiting toxicities (DLT) and to define maximum-tolerated dose (MTD) for a new chemoimmunotherapy combination of bendamustine, ofatumumab, carboplatin, and etoposide in patients with Non Hodgkin's lymphoma whose disease has progressed or has recurred after prior chemotherapy. The Phase II part of the study will be a single-arm, open-label study in which all patients will receive combination bendamustine, ofatumumab, carboplatin and etoposide at the MTD dose defined in phase I. This study hopes to identify a life-prolonging therapy for patients with Non-Hodgkin's Lymphoma whose disease has progressed or has recurred after prior chemotherapy. The hypothesis is that the proposed combination of chemotherapy is well-tolerated and is efficacious for the treatment of relapsed/refractory aggressive B cell lymphomas.	SEP	Phase 1/2	Immunomodulation	United States	À vérifier
PET ScanThe Phase I part of the study will apply to identify dose-limiting toxicities (DLT) and to define maximum-tolerated dose (MTD) for a new chemoimmunotherapy combination of bendamustine, ofatumumab, carboplatin, and etoposide in patients with Non Hodgkin's lymphoma whose disease has progressed or has recurred after prior chemotherapy. The Phase II part of the study will be a single-arm, open-label study in which all patients will receive combination bendamustine, ofatumumab, carboplatin and etoposide at the MTD dose defined in phase I. This study hopes to identify a life-prolonging therapy for patients with Non-Hodgkin's Lymphoma whose disease has progressed or has recurred after prior chemotherapy. The hypothesis is that the proposed combination of chemotherapy is well-tolerated and is efficacious for the treatment of relapsed/refractory aggressive B cell lymphomas.	SEP	Phase 1/2	Immunomodulation	United States	À vérifier
BendamustineResearchers are looking for new ways to treat follicular lymphoma (FL). A standard (usual) treatment for FL includes a targeted therapy called rituximab and chemotherapy. In this study, researchers want to learn if giving a study medicine called MK-1045 and rituximab can treat FL. MK-1045 is a type of treatment called immunotherapy. The goals of this study are to learn: * About the safety of MK-1045 and rituximab, and if people tolerate them when given together * If people who receive MK-1045 and rituximab have the cancer go away * If people who receive MK-1045 and rituximab live longer without their cancer getting worse compared to those who receive standard treatment (rituximab and chemotherapy)	SEP	Phase 1/2	À vérifier	United States	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
Bendamustine	SEP	Phase 1/2	NCT01458366	Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide	COMPLETED

Publications

6

Molécule	Indication / population	Titre	Journal	Date
CT Scan		Potential to improve early detection of lung cancer through expansion of focused and opportunistic screening approaches: a scoping review focusing on potential expansion of screening risk factors and adoption of artificial intelligence models.	Lung cancer management
CT Scan		One-stop photon-counting CT angiography for simultaneous assessment of cardio-cerebrovascular lesions: A case report.	Radiology case reports
CT Scan		Study protocol for the TROG 21.08 VITaL trial: a randomized controlled trial investigating ventilation imaging to improve the quality of life for patients with lung cancer treated with radiation therapy.	Clinical and translational radiation oncology
Bendamustine		A dual green chromatographic platform for bioanalytical quantification and pharmacokinetic characterization of the BBD antineoplastic regimen.	Analytica chimica acta
Bendamustine		Comparative pathogenesis and management of orbital/conjunctival and gastric MALT lymphoma: Microbial drivers, molecular mechanisms, and therapeutic implications.	Survey of ophthalmology
Bendamustine		Follicular Lymphoma Arising in an Ileal Neobladder Presenting as a Large Pelvic Mass.	IJU case reports